A laboratory technician works at a Tsinghua University lab in Beijing. Brii, Tsinghua University and the Third People’s Hospital of Shenzhen have co-developed a monoclonal neutralising antibody therapy. Photo: AFP
A laboratory technician works at a Tsinghua University lab in Beijing. Brii, Tsinghua University and the Third People’s Hospital of Shenzhen have co-developed a monoclonal neutralising antibody therapy. Photo: AFP

Brii Biosciences shares surge after launching China’s first domestically developed Covid-19 drug

  • Hong Kong-listed Brii Biosciences jumped as much as 30 per cent after it announced the commercial launch of its Covid-19 drug
  • Launch of China’s first home-grown Covid-19 medication – Brii-196/Brii-198 – comes amid a flare-up in cases on the mainland

A laboratory technician works at a Tsinghua University lab in Beijing. Brii, Tsinghua University and the Third People’s Hospital of Shenzhen have co-developed a monoclonal neutralising antibody therapy. Photo: AFP
A laboratory technician works at a Tsinghua University lab in Beijing. Brii, Tsinghua University and the Third People’s Hospital of Shenzhen have co-developed a monoclonal neutralising antibody therapy. Photo: AFP
READ FULL ARTICLE